MX2010004615A - Anticuerpos monoclonales contra proteina c. activada e inactivada. - Google Patents

Anticuerpos monoclonales contra proteina c. activada e inactivada.

Info

Publication number
MX2010004615A
MX2010004615A MX2010004615A MX2010004615A MX2010004615A MX 2010004615 A MX2010004615 A MX 2010004615A MX 2010004615 A MX2010004615 A MX 2010004615A MX 2010004615 A MX2010004615 A MX 2010004615A MX 2010004615 A MX2010004615 A MX 2010004615A
Authority
MX
Mexico
Prior art keywords
activated protein
monoclonal antibodies
antibodies against
antibodies
against activated
Prior art date
Application number
MX2010004615A
Other languages
English (en)
Spanish (es)
Inventor
Xu Jun
Charles Esmon
Original Assignee
Oklahoma Med Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Med Res Found filed Critical Oklahoma Med Res Found
Publication of MX2010004615A publication Critical patent/MX2010004615A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
MX2010004615A 2007-10-26 2008-10-24 Anticuerpos monoclonales contra proteina c. activada e inactivada. MX2010004615A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98309207P 2007-10-26 2007-10-26
PCT/US2008/081110 WO2009055669A2 (en) 2007-10-26 2008-10-24 Monoclonal antibodies against activated and unactivated protein c

Publications (1)

Publication Number Publication Date
MX2010004615A true MX2010004615A (es) 2010-07-06

Family

ID=40289112

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004615A MX2010004615A (es) 2007-10-26 2008-10-24 Anticuerpos monoclonales contra proteina c. activada e inactivada.

Country Status (13)

Country Link
US (3) US8153766B2 (enExample)
EP (1) EP2205638B1 (enExample)
JP (3) JP2011500843A (enExample)
KR (2) KR101856210B1 (enExample)
CN (3) CN103232541A (enExample)
AU (1) AU2008316661B2 (enExample)
BR (1) BRPI0818865A2 (enExample)
CA (1) CA2703738C (enExample)
IL (2) IL205284A (enExample)
MX (1) MX2010004615A (enExample)
RU (2) RU2539729C2 (enExample)
WO (1) WO2009055669A2 (enExample)
ZA (1) ZA201105704B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2664473C2 (ru) * 2012-03-16 2018-08-17 Регенерон Фармасьютикалз, Инк. ОТЛИЧНЫЕ ОТ ЧЕЛОВЕКА ЖИВОТНЫЕ, ЭКСПРЕССИРУЮЩИЕ ЧУВСТВИТЕЛЬНЫЕ К pН ПОСЛЕДОВАТЕЛЬНОСТИ ИММУНОГЛОБУЛИНОВ
EP2925351A4 (en) * 2012-11-29 2016-08-24 Bayer Healthcare Llc MONOCLONAL ANTIBODIES DIRECTED AGAINST ACTIVATED PROTEIN C (APC)
KR20150088853A (ko) * 2012-11-29 2015-08-03 바이엘 헬스케어 엘엘씨 활성화 단백질 c에 대한 인간화 모노클로날 항체 및 그의 용도
EP3047857A4 (en) * 2013-09-20 2017-08-09 Chugai Seiyaku Kabushiki Kaisha Treatment for hemorrhagic diseases by anti-protein-c antibody
GB201322091D0 (en) 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
WO2015179435A1 (en) * 2014-05-19 2015-11-26 Bayer Healthcare Llc Optimized humanized monoclonal antibodies against activated protein c and uses thereof
US11077187B2 (en) 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
CN116284402A (zh) 2016-12-21 2023-06-23 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
KR102742528B1 (ko) 2017-06-20 2024-12-16 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
TW201906868A (zh) * 2017-07-07 2019-02-16 日商第一三共股份有限公司 抗蛋白ｃ抗體
US11447546B2 (en) 2017-07-20 2022-09-20 Nbe-Therapeutics Ag Human antibodies binding to ROR2
JP7346389B2 (ja) * 2017-09-13 2023-09-19 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 異常な血小板レベルのマーカーとしてのプロアドレノメジュリン
US12319744B2 (en) 2018-09-06 2025-06-03 Board Of Regents, The University Of Texas System Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein C receptor (EPCR)
AU2019360758B2 (en) * 2018-10-18 2024-08-08 Oklahoma Medical Research Foundation Biomarkers for a Systemic Lupus Erythematosus (SLE) disease activity immune index that characterizes disease activity
CN109897108B (zh) * 2019-03-11 2021-04-02 上海恒赛生物科技有限公司 抗人内皮蛋白c受体的羊驼单域抗体及应用
CN115611986B (zh) * 2021-07-13 2025-08-12 上海莱士血液制品股份有限公司 针对人活化蛋白c的单克隆抗体及其制备和应用
CN118370814A (zh) * 2023-01-20 2024-07-23 上海莱士血液制品股份有限公司 一种抗aPC单克隆抗体的制剂及其应用
KR20250000042A (ko) 2023-06-23 2025-01-02 충남대학교산학협력단 절단 반응성 펩타이드를 발현하는 키메라 t 세포 및 이를 포함하는 감염 질환 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247453B1 (en) * 1988-12-30 2007-07-24 Oklahoma Medical Research Foundation Calcium binding recombinant antibody against protein C
US5202253A (en) * 1988-12-30 1993-04-13 Oklahoma Medical Research Foundation Monoclonal antibody specific for protein C and antibody purification method
US5279956A (en) * 1991-06-24 1994-01-18 The Scripps Research Institute Activated protein C polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibiting activated protein C
US5695993A (en) 1994-08-12 1997-12-09 Oklahoma Medical Research Foundation Cloning and regulation of an endothelial cell protein C/activated protein C receptor
US6953568B1 (en) 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
AU2001296483B2 (en) * 2000-10-02 2006-02-16 Oklahoma Medical Research Foundation Assay for rapid detection of human activated protein C and highly specific monoclonal antibody therefor
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same

Also Published As

Publication number Publication date
AU2008316661A1 (en) 2009-04-30
KR20100116166A (ko) 2010-10-29
JP6117741B2 (ja) 2017-04-19
RU2539729C2 (ru) 2015-01-27
BRPI0818865A2 (pt) 2015-05-05
KR20150092358A (ko) 2015-08-12
CA2703738C (en) 2018-02-27
ZA201105704B (en) 2014-05-28
KR101856210B1 (ko) 2018-05-09
US20120164150A1 (en) 2012-06-28
WO2009055669A3 (en) 2009-09-03
IL205284A0 (en) 2010-12-30
CA2703738A1 (en) 2009-04-30
IL205284A (en) 2014-06-30
CN105153308A (zh) 2015-12-16
EP2205638A2 (en) 2010-07-14
EP2205638B1 (en) 2017-03-01
IL220622A0 (en) 2012-08-30
US8153766B2 (en) 2012-04-10
US20090110683A1 (en) 2009-04-30
RU2010121148A (ru) 2011-12-10
JP2011500843A (ja) 2011-01-06
AU2008316661B2 (en) 2013-05-23
RU2012150953A (ru) 2014-06-10
WO2009055669A2 (en) 2009-04-30
JP2014237651A (ja) 2014-12-18
JP2013049694A (ja) 2013-03-14
CN101918453A (zh) 2010-12-15
US20150344588A1 (en) 2015-12-03
US9127072B2 (en) 2015-09-08
CN103232541A (zh) 2013-08-07

Similar Documents

Publication Publication Date Title
MX2010004615A (es) Anticuerpos monoclonales contra proteina c. activada e inactivada.
CY1125011T1 (el) Ενεργοποιουμενα αντισωματα enanti-cd71 και μεθοδοι χρησης αυτων
CY1124408T1 (el) ΣΤΟΧΕΥΜΕΝΗ ΑΝΑΣΤΟΛΗ TGFβ
CY1116488T1 (el) Αντισωματα anti-προπερδινης
PH12016502064A1 (en) Human antibodies to middle east respiratory syndrome-coronavirus spike protein
CY1120665T1 (el) Ανθρωποποιημενα αντισωματα anti-cxcr5, παραγωγα αυτων και χρησεις τους
CY1123030T1 (el) Υλικο και μεθοδοι για θεραπεια ή αποτροπη σχετικων me her-3 ασθενειων
CL2019003520A1 (es) Anticuerpos que se unen específicamente a pd-1 y procedimientos de uso.
CR11691A (es) Anticuerpos monoclonales contra la proteína rgm a y sus usos
MX385545B (es) Anticuerpos humanos para pd-1.
GT200900002A (es) Anticuerpo antagonista para el tratamiento del cancer
BRPI0919473A2 (pt) Agentes de ligação frizzled e usos dos mesmos
EA200901119A1 (ru) АНТИТЕЛА ПРОТИВ ErbB3 И ИХ ПРИМЕНЕНИЕ
BR112019010595A2 (pt) anticorpo ou fragmento de ligação ao antígeno do mesmo, combinação de moléculas de ácido nucleico isoladas, composição farmacêutica, kit, e, método para selecionar um composto.
ES2633597T3 (es) Anticuerpos con afinidad modificada para FcRn que promueven la eliminación del antígeno
CR10068A (es) Anticuerpos anti mn y métodos para su utilización
BR112017027549A2 (pt) anticorpo para cd40
CY1115639T1 (el) Διειδικα αγωνιστικα αντισωματα υποδοχεα θανατου
EA201070179A1 (ru) Антиген, связанный с вариантами рака легкого и лимфомами
CR20120371A (es) Antagonistas de pcsk9
GT201200132A (es) Antagonistas il-17a
MX2009006471A (es) Anticuerpo anti especifico de linfopoyetina estromal timica de diseño.
UY32612A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c3b
BR112018012344A2 (pt) anticorpos que se ligam especificamente a hla-dr e seus usos
CY1119154T1 (el) Anti-vla-4 αντισωματα

Legal Events

Date Code Title Description
FG Grant or registration